FI107701B - Menetelmä parannettujen kylmäkuivattujen ifosfamidikoostumuksien valmistamiseksi - Google Patents

Menetelmä parannettujen kylmäkuivattujen ifosfamidikoostumuksien valmistamiseksi Download PDF

Info

Publication number
FI107701B
FI107701B FI924797A FI924797A FI107701B FI 107701 B FI107701 B FI 107701B FI 924797 A FI924797 A FI 924797A FI 924797 A FI924797 A FI 924797A FI 107701 B FI107701 B FI 107701B
Authority
FI
Finland
Prior art keywords
ifosfamide
weight
lyophilisate
compositions
urea
Prior art date
Application number
FI924797A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI924797A (fi
FI924797A0 (fi
Inventor
Robert Lee Alexander
Robert Joseph Behme
Joseph Arthur Scott
Dana Brooke
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of FI924797A0 publication Critical patent/FI924797A0/fi
Publication of FI924797A publication Critical patent/FI924797A/fi
Application granted granted Critical
Publication of FI107701B publication Critical patent/FI107701B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI924797A 1991-10-23 1992-10-22 Menetelmä parannettujen kylmäkuivattujen ifosfamidikoostumuksien valmistamiseksi FI107701B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78143691 1991-10-23
US07/781,436 US5227373A (en) 1991-10-23 1991-10-23 Lyophilized ifosfamide compositions

Publications (3)

Publication Number Publication Date
FI924797A0 FI924797A0 (fi) 1992-10-22
FI924797A FI924797A (fi) 1993-04-24
FI107701B true FI107701B (fi) 2001-09-28

Family

ID=25122737

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924797A FI107701B (fi) 1991-10-23 1992-10-22 Menetelmä parannettujen kylmäkuivattujen ifosfamidikoostumuksien valmistamiseksi

Country Status (24)

Country Link
US (1) US5227373A (de)
EP (1) EP0538858B1 (de)
JP (1) JP3576180B2 (de)
KR (1) KR100247161B1 (de)
CN (1) CN1046202C (de)
AT (1) ATE175354T1 (de)
AU (1) AU658011B2 (de)
CA (1) CA2081061A1 (de)
CZ (1) CZ282445B6 (de)
DE (1) DE69228105T2 (de)
DK (1) DK0538858T3 (de)
EG (1) EG20114A (de)
ES (1) ES2125880T3 (de)
FI (1) FI107701B (de)
GR (1) GR3029835T3 (de)
HU (2) HU221428B (de)
IL (1) IL103496A (de)
MX (1) MX9206105A (de)
MY (1) MY109794A (de)
NZ (1) NZ244816A (de)
RU (1) RU2106138C1 (de)
SK (1) SK279869B6 (de)
TW (1) TW217987B (de)
ZA (1) ZA928104B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
DE19733305A1 (de) * 1997-08-01 1999-02-04 Asta Medica Ag Pharmazeutische Zusammensetzung enthaltend Ifosfamid und Carnitin
ATE348621T1 (de) * 1997-10-13 2007-01-15 Stada Arzneimittel Ag Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
ATE397440T1 (de) * 2002-02-22 2008-06-15 Schering Corp Pharmazeutische zubereitungen von antineoplastischen wirkstoffen, insbesondere temozolomid, verfahren zu ihrer herstellung und deren verwendung
BR0314068A (pt) * 2002-09-05 2005-07-05 Bharat Serums & Vaccines Ltd Processo para a preparação de uma composição estável com baixo nìvel de toxicidade; composição estável que contém oxazafosforina; uso de uma composição estável que contém oxazafosforina; e método de tratamento de uma doença maligna
MXPA05005919A (es) * 2002-12-02 2005-09-21 Bharat Serums & Vaccines Ltd Composiciones de ifosfamida para la administracion parenteral, y un proceso para su preparacion.
US7199111B2 (en) * 2002-12-02 2007-04-03 Bharat Serums & Vaccines Ltd. Aqueous ifosfamide compositions for parenteral administration and a process for their preparations
DK1667655T3 (da) * 2003-10-01 2011-10-24 Baxter Int Ny anvendelse, farmaceutiske præparater og en fremgangsmåde til deres fremstilling
EP1814544A4 (de) * 2004-11-05 2009-12-02 Cephalon Inc Krebsbehandlungen
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2007079147A2 (en) 2005-12-28 2007-07-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
EP2071917B1 (de) * 2006-09-29 2012-11-21 Infa S.A. Verpackungssystem für pharmazeutische zusammensetzungen und kit zur intravenösen verabreichung
CA2673120C (en) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation A dry food product containing live probiotic
WO2008140724A1 (en) * 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (de) * 2008-09-25 2015-07-01 Cephalon, Inc. Flüssige Formulierungen aus Bendamustin
KR20110110293A (ko) * 2009-01-15 2011-10-06 세파론, 인코포레이티드 벤다무스틴 유리 염기의 신규 형태
EP3266448B1 (de) 2009-03-27 2022-02-16 Intervet International B.V. Impfstoffe in mikropartikelform zur oralen oder nasalen impfung und stärkung von tieren einschliesslich fischen
CN102459568A (zh) * 2009-05-26 2012-05-16 先进生物营养公司 包含生物活性微生物和/或生物活性材料的稳定干粉组合物及其制造方法
SG182317A1 (en) 2010-01-28 2012-08-30 Advanced Bionutrition Corp Dry glassy composition comprising a bioactive material
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
RS57588B1 (sr) 2010-08-13 2018-11-30 Advanced Bionutrition Corp Supstanca za stabilizaciju bioloških materijala za suvo skladištenje
WO2015101665A1 (en) 2014-01-06 2015-07-09 Auxin Surgery Sa Lyophilized mesna compositions
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
AU2016297986B8 (en) 2015-07-29 2020-06-11 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
JP6706988B2 (ja) * 2016-07-20 2020-06-10 日本化薬株式会社 ボルテゾミブを含有する医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
ZA851062B (en) * 1984-03-01 1985-11-27 Asta Werke Ag Chem Fab Salts of oxazaphosphorine derivatives and process for their production
ATE66609T1 (de) * 1986-07-11 1991-09-15 Asta Pharma Ag Loesungen von oxazaphosphorinen mit verbesserter stabilitaet und verfahren zu deren herstellung.
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
EP0281832B1 (de) * 1987-03-06 1991-05-02 ASTA Pharma Aktiengesellschaft Verfahren zur Herstellung von Ifosfamid mit verbesserten Eigenschaften
ES2040394T3 (es) * 1988-03-19 1993-10-16 Asta Medica Aktiengesellschaft Procedimiento para preparar un material liofilizado de ifosfamida y mesna.
US5036060A (en) * 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide

Also Published As

Publication number Publication date
HUT69384A (en) 1995-09-28
JP3576180B2 (ja) 2004-10-13
FI924797A (fi) 1993-04-24
NZ244816A (en) 1994-06-27
AU2716692A (en) 1993-04-29
SK279869B6 (sk) 1999-04-13
AU658011B2 (en) 1995-03-30
MX9206105A (es) 1993-04-01
JPH05246856A (ja) 1993-09-24
CA2081061A1 (en) 1993-04-24
EP0538858B1 (de) 1999-01-07
DK0538858T3 (da) 1999-08-30
MY109794A (en) 1997-06-30
US5227373A (en) 1993-07-13
CZ317692A3 (en) 1993-09-15
HU211293A9 (en) 1995-11-28
KR930007453A (ko) 1993-05-20
TW217987B (de) 1993-12-21
CN1073358A (zh) 1993-06-23
CZ282445B6 (cs) 1997-07-16
DE69228105T2 (de) 1999-08-26
IL103496A0 (en) 1993-03-15
CN1046202C (zh) 1999-11-10
ZA928104B (en) 1993-07-20
EG20114A (en) 1997-07-31
KR100247161B1 (ko) 2000-04-01
ES2125880T3 (es) 1999-03-16
HU221428B (en) 2002-10-28
ATE175354T1 (de) 1999-01-15
HU9203306D0 (en) 1992-12-28
GR3029835T3 (en) 1999-06-30
RU2106138C1 (ru) 1998-03-10
SK317692A3 (en) 1995-11-08
DE69228105D1 (de) 1999-02-18
EP0538858A1 (de) 1993-04-28
FI924797A0 (fi) 1992-10-22
IL103496A (en) 1996-07-23

Similar Documents

Publication Publication Date Title
FI107701B (fi) Menetelmä parannettujen kylmäkuivattujen ifosfamidikoostumuksien valmistamiseksi
US4537883A (en) Lyophilized cyclophosphamide
TWI548414B (zh) 達托黴素（ｄａｐｔｏｍｙｃｉｎ）組合物及相關方法
CN101039660B (zh) 稳定的聚乙二醇化干扰素制剂
JP4142149B2 (ja) バンコマイシンの凍結乾燥製剤
US5750131A (en) Ifosfamide lyophilizate preparations
US20160256557A1 (en) Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
EP0656211B1 (de) Stabilisiertes Thiotepa-Lyophilisat
US5227374A (en) Lyophilized cyclophosphamide
AU1769501A (en) Stable amorphous amifostine composition, and preparation thereof
US5972912A (en) Method for lyophilizing ifosfamide
WO2015025000A1 (en) Pharmaceutical compositions comprising bortezomib
SK284311B6 (sk) Stabilizované farmaceutické prostriedky založené na chinupristíne a dalfopristíne a spôsob ich prípravy
WO2001047542A1 (fr) Preparations de vancomycine
US20240082253A1 (en) Lyophilized composition of copanlisib salt
GB2271281A (en) Stabilised cyclophosphamide compositions
CA2503087A1 (en) Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
EP3035914A1 (de) Pharmazeutische zusammensetzungen mit bortezomib